[Current developments in urothelial carcinoma]
- PMID: 39373754
- DOI: 10.1007/s00120-024-02442-z
[Current developments in urothelial carcinoma]
References
Literatur
-
- Powles T et al (2021) A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA). Clin Oncol 39(6_suppl):TPS505–TPS505
Publication types
MeSH terms
LinkOut - more resources
Medical